Market Overview

Endo to Acquire NuPathe for $2.85/Share in Cash


Endo Health Solutions (Nasdaq: ENDP) today announced it has entered into a definitive agreement under which Endo will acquire NuPathe Inc. (Nasdaq: PATH) for $2.85 per share in cash, or approximately $105 million.  In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment ZECUITY are achieved over time.  Endo expects meaningful cost synergies from the transaction, which is expected to be accretive to Endo's adjusted diluted earnings per share within the first 12 months of closing. 

See full press release

Posted-In: News Guidance Contracts Management M&A Global


Related Articles (ENDP + PATH)

View Comments and Join the Discussion!

Agenus Announces Positive Phase 2 Brain Cancer Vaccine Results Published in Neuro-Oncology

#PreMarket Primer for December 16: Japan's Tankan Survey Shows Broad Improvement